Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03802851 · ClinicalTrials.gov registry record · NA

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

A NA study of Prostate Cancer and Lower Urinary Tract Symptoms, sponsored by University of Kansas Medical Center.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03802851: Recruiting NA study of Prostate Cancer and Lower Urinary Tract Symptoms, sponsored by University of Kansas Medical Center.

NCT03802851 is a NA study of Prostate Cancer and Lower Urinary Tract Symptoms that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03802851, a NA study of Prostate Cancer and Lower Urinary Tract Symptoms, is actively recruiting participants, sponsored by University of Kansas Medical Center.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.

Primary Outcome

The primary object is to determine if holmium laser enucleation of the prostate (HoLEP) improves the quality of life in patients with concurrent prostate cancer who may undergo radiation therapy as well. Quality of life will be assessed using the Expanded Prostate Cancer Index Composite (EPIC) 26. This instrument evaluates patient function and bother after prostate cancer treatment using 26 items and scored on a 0-100 scale, with higher scores indicating a better health related quality of life.

Interventions

  • PROCEDURE Holmium Laser Enucleation of Prostate (HoLEP)

Study Locations (1)

Kansas

  • University of Kansas Health System - Kansas City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-09-19
Est. Completion 2035-01
Phase NA
University of Kansas Medical Center

408 total trials

What NCT03802851 shows while recruiting

NCT03802851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Holmium Laser Enucleation of Prostate (HoLEP) is the first listed.

NCT03802851 reports a single indexed study location in Kansas.

Frequently Asked Questions

What is clinical trial NCT03802851 about?

NCT03802851 is a clinical study titled "HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer". To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.

What is the current status of trial NCT03802851?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2019-09-19. Estimated completion is 2035-01.

What conditions does trial NCT03802851 study?

This clinical trial studies the following conditions: Prostate Cancer, Lower Urinary Tract Symptoms.

What interventions are being tested in trial NCT03802851?

The interventions under investigation include: Holmium Laser Enucleation of Prostate (HoLEP) (PROCEDURE).

Who is sponsoring clinical trial NCT03802851?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03802851 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03802851's enrollment target sits among peer trials

30 583rd of 735 higher than 128 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03802851, the US trial registry maintained by the National Library of Medicine. NCT03802851 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.